(CHRS) to Present at Bloomberg Biosimilars Conference on November 2

REDWOOD CITY, Calif., Oct. 27, 2015  — Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will participate in several panel discussions regarding development, regulatory, policy, analytics, commercialization, and other key industry issues at the Bloomberg Intelligence Biosimilars Conference. Juliana Reed, the President of the Biosimilar Forum and Coherus Vice President of Government Affairs, will be giving the keynote address.

The conference will be held on Monday, November 2 starting at 12:30 pm ET in New York City. Information regarding the discussions is available at http://b.bloomberg.com/2015Biosimilars-regform-sales.

About Coherus BioSciences, Inc.

Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products.

For additional information, please visit www.coherus.com.

CONTACT:
Keith Vendola, M.D.
Investor Relations
Coherus BioSciences, Inc.
kvendola@coherus.com
+1 (650) 437-6239